Akebia Therapeutics (AKBA) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 3[1], 1 Phase 2[2].
Trial NCT06901505[4] evaluates Erythropoiesis-Stimulating Agent (ESA) in Anemia of Chronic Kidney Disease with a target enrollment of 353 participants.
AKBA has 1 Form 4 insider filing recorded at the SEC in the past 30 days[5].